| DB ID | MyCo_3191 |
| Title | Serum β-d-glucan of critically ill patients with suspected ventilator-associated pneumonia: preliminary observations |
| Year | 2011 |
| PMID | 21376516 |
| Fungal Diseases involved | Ventilator-associated pneumonia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | Local institutional research ethics boards approved the original protocol, and informed consent was obtained before enrollment. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Canada |
| Cohort | Fifty-seven patients were included; 26 had no growth, 19 patients grew pathogenic bacteria only, and 12 patients grew only Candida. |
| Cohort No. | 57 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Ventilator-associated pneumonia (VAP) is one of the most common acquired infections complicating critical illness and results in considerable attributable morbidity and mortality. These attributable morbidity and mortality vary, among other things, on the nature of the infection, the infecting organism, and the adequacy of empiric therapy. In a recent multicenter study of patients with suspected VAP, we demonstrated that those who grew an identifiable pathogen in respiratory tract cultures (“culture positive”) had a much better outcome than those who did not have an identifiable pathogen in the culture (“culture negative”). Historically, Candida sp present in respiratory tract secretions of critically ill patients were considered as colonizing microorganisms or contaminants. |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
